ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. This approach will provide critical insights for the clinical translation of WSD0628 for the treatment of primary and secondary brain tumors.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Treatment DNA 100

ASPET

SEPTEMBER 16, 2024

GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Acknowledging the potential for inter-species differences in pharmacokinetics, these data suggest that clinical translation of elimusertib in combination with temozolomide for treatment of GBM may be limited.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

ASPET

FEBRUARY 26, 2024

Panobinostat is a potent pan-HDAC inhibitor that has been tested in multiple studies for the treatment of brain tumors. There have been contrasting views surrounding its efficacy for the treatment of tumors in the CNS following systemic administration when examined in different models or species.

Metabolic Stability 100

Metabolic Stability Pharmacokinetics Pharmacogenetics Treatment 100

ASPET

OCTOBER 12, 2023

Panobinostat is a nonselective pan-HDAC inhibitor that is being tested in pre-clinical and clinical studies, including for the treatment of pediatric medulloblastoma, which has a propensity for leptomeningeal spread, and diffuse midline glioma (DMG), which can infiltrate into supratentorial brain regions.

Pharmacogenetics 100

Pharmacogenetics Clinical Trials Treatment Therapies 100

ASPET

MARCH 6, 2024

The contrary was observed, when microsomes isolated from treatment naive animals were assessed for the OSI-420 formation after erlotinib exposure. Microsomes isolated from the treated animals were characterized for CYP3A activity using testosterone, showing higher activity in the knock-in rats.

Protein Expression 100

Protein Expression Pharmacogenetics Treatment Drugs 100

The Open Targets Blog

NOVEMBER 30, 2023

Introducing pharmacogenetics data to the Platform This release introduces a new datasource to the Platform: the pharmacogenetics widget will incorporate data about the impact of human genetic variation on drug responses. You can find this data on the target and drug profile pages.

Pharmacogenetics 59

Pharmacogenetics Small Molecule Disease Drugs 59

The Pharma Data

OCTOBER 27, 2020

Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). There is a better way to get every patient the treatment they deserve. We believe that DXRX is that way.

Pharmacogenetics 40

Pharmacogenetics Laboratories Therapies Hospitals 40